PURPOSE: To determine whether proton magnetic resonance (MR) spectroscopic imaging is a sensitive technique for defining tumor extent and assessing response of cerebral lymphoma to therapy. MATERIALS AND METHODS: Four hydrogen-1 MR spectroscopic imaging studies were performed in a patient with non-Hodgkin lymphoma (NHL) before, during, and after radiation therapy and at follow-up at 33 months after diagnosis of the recurrence of disease. The patient had a single, large lesion in the brain and underwent hyperfractionated radiation therapy for 4 weeks. A series of MR images was also obtained. RESULTS: The pretreatment study showed a lesion with a distinct spectral pattern: marked elevation of choline and lipids and great reduction of creatine and N-acetylaspartate. During and after treatment, H-1 MR spectroscopic images depicted a progressive reduction of the abnormal choline and lipid signals. Thirty-three months after treatment, multiple- section H-1 MR spectroscopic images showed normal spectral patterns in all sections examined. CONCLUSION: H-1 MR spectroscopy may contribute to the neuroradiologic evaluation of NHL and, in particular, may be useful in monitoring therapeutic response.
- Brain neoplasms, emission CT
- Brain neoplasms, secondary
- Hodgkin disease, therapeutic radiology
- Magnetic resonance (MR), spectroscopy
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging